readthroughSign in
CompanyVERUNasdaqMiami, FL

Veru Inc.

Veru develops sabizabulin, an oral microtubule-targeting agent that inhibits microtubule polymerization to disrupt cancer cell proliferation and induce apoptosis across multiple tumor types, including taxane-resistant cancers.

10-QNov 16Latest SEC filing
Sep 8Latest story